SPYH:XETRA:XETRA-

| Sector Equity Healthcare |

Last Closing

USD 225.1

Change

-1.40 (-0.62)%

Market Cap

USD 0.66B

Volume

144.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-11 )

Largest Industry Peers for Sector Equity Healthcare

Symbol Name Price(Change) Market Cap
QDVG:XETRA

-0.04 (-0.38%)

USD 2.05B
2B78:XETRA

-0.06 (-0.77%)

USD 1.14B
XUHC:XETRA

-0.17 (-0.30%)

USD 0.85B
LYPE:XETRA

-2.10 (-0.42%)

USD 0.78B
LHTC:XETRA

-1.16 (-0.76%)

USD 0.73B
EXV4:XETRA

-0.60 (-0.51%)

USD 0.70B
ESIH:XETRA

-0.09 (-1.22%)

USD 0.60B
2B77:XETRA

-0.04 (-0.57%)

USD 0.50B
ZPDH:XETRA

-0.14 (-0.32%)

USD 0.40B
DXSE:XETRA

-1.40 (-0.60%)

USD 0.14B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Sector Equity Healthcare) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.60% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.60% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 8.98% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.98% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 33.16% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.16% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.37% 61% D- 61% D-
Dividend Return 9.37% 60% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.02% 71% C- 77% C+
Risk Adjusted Return 116.79% 96% N/A 96% N/A
Market Capitalization 0.66B N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike